Table 3.

Correlation of biomarker results with overall survival (OS) and progression-free survival (PFS)

Biomarker	n	OS			PFS
		Mos.	HR (95 % CI)	P	Mos.	HR (95 % CI)	P
KRAS
Wild-type	309	NR			12.5
Mutation	9	67.0	1.08 (0.43–2.69)	0.876	14.1	0.90 (0.42–1.91)	0.784
PIK3CA
Wild-type	306	67.0			12.4
Mutation	12	NR	0.53 (0.17–1.65)	0.262	NR	0.36 (0.15–0.86)	0.017
EGFR
Wild-type	315	NR			12.9
Mutation	3	37.9	1.80 (0.53–6.15)	0.345	4.01	2.09 (0.67–6.54)	0.195
KRAS, NRAS, BRAF, PIK3CA or EGFR
Wild-type	294	NR			12.3
Mutation	24	67.0	0.75 (0.38–1.49)	0.413	33.1	0.57 (0.33–0.99)	0.042
EGFR IHC
Negative	125	51.0			11.7
Positive	93	46.1	1.23 (0.85–1.78)	0.273	13.0	1.03 (0.76–1.39)	0.835
EGFR FISH
Negative	114	67.0			16.1
Positive	66	46.1	1.56 (1.01–2.40)	0.044	9.6	1.57 (1.11–2.22)	0.010
pAkt-IHC
Negative	108	49.1			11.6
Positive	27	53.7	0.89 (0.48–1.63)	0.696	13.8	0.65 (0.39–1.09)	0.100
pMAPK-IHC
Negative	70	67.0			15.7
Positive	58	38.9	1.81 (1.11–2.97)	0.016	8.1	1.42 (0.96–2.10)	0.077
E-cadherin-IHC
Negative	64	67.0			10.5
Positive	71	51.0	0.99 (0.61–1.62)	0.970	13.1	0.87 (0.59–1.28)	0.491
Vimentin-IHC
Negative	30	NR			13.8
Intermediate	58	49.0	1.61 (0.78–3.30)		13.1	0.88 (0.53–1.45)
Positive	40	39.6	2.07 (0.99–4.34)	0.139	9.1	1.18 (0.70–1.98)	0.430
HER2-FISH
Negative	30	49.1			22.1
Equivocal	23	51.0	1.07 (0.48–2.35)		8.8	2.13 (1.13–4.01)
Positive	53	67.0	0.97 (0.49–1.89)	0.965	13.7	1.51 (0.87–2.63)	0.061

CI confidence interval, FISH fluorescence in situ hybridization, HR hazard ratio, IHC immunohistochemistry, Mos. months, NR not reached, OS overall survival, PFS progression-free survival. Bold entries indicate statistically significant p values (P <0.05)